Sivelestat Alleviates Atherosclerosis by Improving Intestinal Barrier Function and Reducing Endotoxemia.

ABSTRACT: Emerging evidence suggests that atherosclerosis, one of the leading phenotypes of cardiovascular diseases, is a chronic inflammatory disease. During the atherosclerotic process, immune cells play critical roles in vascular inflammation and plaque formation. Meanwhile, gastrointestinal disorder is considered a risk factor in mediating the atherosclerotic process. The present study aimed to utilize sivelestat, a selective inhibitor of neutrophil elastase, to investigate its pharmacological benefits on atherosclerosis and disclose the gastrointestinal-vascular interaction. The activation of intestinal neutrophil was increased during atherosclerotic development in Western diet-fed ApoE^-/- mice. Administration of sivelestat attenuated atherosclerotic phenotypes, including decreasing

SUBMITTER: Nie H 

PROVIDER: S-EPMC9014170 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature